NSC-70220
Based on 1 Customer Validation
NSC-70220 is a selective and allosteric SOS1 inhibitor. NSC-70220 inhibits allosteric site activation, and partially inhibited catalytic site activation. NSC-70220 has an anticancer effect.
For research use only. We do not sell to patients.
- Purity: 99.42%
- CAS No.: 4551-00-2
- Formula: C22H15NO2
- Molecular Weight:325.36
-
Storage:Powder -20°C, 3 years , 4°C, 2 years
* The compound is unstable in solutions, freshly prepared is recommended.
Biological Activity
SOS1[1].
The growth inhibitory rate (IR)=(average OD value in the control group-average OD value in the treatment group)/average OD value in the control group×100% are compared. Treatments with NSC-70220 at 40 μM and NSC-658497 at 30 μM result in growth inhibitory rate of 29% and 8% respectively. The combination treatment results in growth inhibitory rate of 54%, showing the synergistic effect of NSC-70220 and NSC-658497 on cell growth inhibition. It is showed that the treatment with NSC-658497 at 40 μM for 2 hours alone or in combìnation with the treatment with 40 μM of NSC-70220 overnight resulted in lower expression levels of P-AKT and P-ERK. The treatment wlth 40 μM of NSC-70220 overnight resulted in lower expression levels of P-ERK[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 4551-00-2
-
Appearance Solid
-
Molecular Weight 325.36
-
Formula C22H15NO2
-
Color Light yellow to yellow
-
SMILES
O=[N+]([O-])C1=CC=CC=C1/C=C/C=C2C3=CC=CC=C3C4=CC=CC=C\24
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years * The compound is unstable in solutions, freshly prepared is recommended.
Solvent & Solubility
DMSO : 12.5 mg/mL (38.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.84 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
MIA paca-2 cells (KRAS G12 C) are subjected to a 3-day proliferation assay following treatment with SOS1-IN-1 (NSC-70220: 40 μM), treatment with NSC-658497 (30 μM) and treatment with a combination of SOS1-IN-1 (40 μM) and NSC-658497 (30 μM). DMSO is used as the negative control[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0735 mL | 15.3676 mL | 30.7352 mL | 76.8380 mL |
| 5 mM | 0.6147 mL | 3.0735 mL | 6.1470 mL | 15.3676 mL | |
| 10 mM | 0.3074 mL | 1.5368 mL | 3.0735 mL | 7.6838 mL | |
| 15 mM | 0.2049 mL | 1.0245 mL | 2.0490 mL | 5.1225 mL | |
| 20 mM | 0.1537 mL | 0.7684 mL | 1.5368 mL | 3.8419 mL | |
| 25 mM | 0.1229 mL | 0.6147 mL | 1.2294 mL | 3.0735 mL | |
| 30 mM | 0.1025 mL | 0.5123 mL | 1.0245 mL | 2.5613 mL |